{"name":"Immune Response BioPharma, Inc.","slug":"immune-response-biopharma-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"IFA Incomplete Freund's Adjuvant","genericName":"IFA Incomplete Freund's Adjuvant","slug":"ifa-incomplete-freund-s-adjuvant","indication":"Other","status":"phase_2"},{"name":"IR103","genericName":"IR103","slug":"ir103","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"IFA Incomplete Freund's Adjuvant","genericName":"IFA Incomplete Freund's Adjuvant","slug":"ifa-incomplete-freund-s-adjuvant","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"IR103","genericName":"IR103","slug":"ir103","phase":"phase_3","mechanism":"IR103 is an immunotherapeutic agent designed to modulate immune response, likely through activation or enhancement of anti-tumor immunity.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxQcTJpMmYzOEsya3VSOXRJelVqOFZEaERHS0lOOVVhc19nNFJZZ2h1M3NaTUpycjFiRkNVT2kzMkpzNjRCQXJoTDZFVjVZSVQ3bmtrTEhtamhVSURkM3J0V1phclR0aElOWU1kRmJoVHc1dVFLQkd6MnhkQXF6QzZoY3UtRTBqMkVuYWdJWm0zQ0RuTkp6amxZSjMxeENZbklQQzBwbXhpbDhvbmgybWI2QUJpd182ZHpYTXplZHI5QmZUSmFUM3pjYVlLZE1MMFExaHI3a0tJNkw0ekRONjRaSkJrSTZQMVNqdFQyY0ZqNDBDR0R2YnVnYzVTeHh1UDBFdHg2T0hxdWxZWGg3QUlyNnFCR08?oc=5","date":"2026-02-20","type":"deal","source":"Business Wire","summary":"ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - Business Wire","headline":"ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE4xMHVKU1RITHdrZjVaUW1md05BUnU3UzhLMG82YXJHUWtDYnpMTDFEU051UjVWVlFDLTcyb3dpQTZQcTVnempQbmM0ekhjeVBPVlp2NDJyMHl1QllIR3ZF?oc=5","date":"2026-01-13","type":"trial","source":"nature.com","summary":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson - nature.com","headline":"Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBKQjVRa3Fjay05WEdjelFUYkNVdVQ5VFFPYk42eGRvLXpTOVJYdHJaTjY4RjE3VHlmOWM0SDV1QmZKNEJXTmg0YVd2eEptbllhaklWQy1vRWdwNC1aUmptb1BfdGZLUQ?oc=5","date":"2026-01-05","type":"regulatory","source":"Fierce Pharma","summary":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products - Fierce Pharma","headline":"2025 drug approvals: Despite FDA tumult and macro uncertainty, biopharma scored with 55 new products","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNdEVoT1JVY3JERzlub0dZTnpnN0NWUGJYMk9EaXI5QmdsamJKNk00UnI2ZHQ5RXdEVVNJTElrT2dzeFBWVUpsUEtwWEpjekY2dWJXZm1feWd2ell3cGZtejZvMC1qeEFfQXBWNWlaSTExMVh6dmtzS1F3UkxVVG5MaUZyR3VSTEtubWhMRnpWU0ZDZFVx?oc=5","date":"2025-12-11","type":"trial","source":"BioPharma Dive","summary":"AC Immune posts positive data for Parkinson’s immunotherapy - BioPharma Dive","headline":"AC Immune posts positive data for Parkinson’s immunotherapy","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE03aDNDcFM5LUc1LVhhUHN4Q3FPX2FjR2dXbjg5OGQ5b3lJX1V6bWI5a1NHOWJDU05OXzIzLUlKSzNTeTh6bHMtSjJkV21UdzhKY1dHMi05RUlTVU1HalJXTWlVbG5LVDIzZDk4dDZn0gFyQVVfeXFMT1dPbWItYzVibXo1ZGJSTHBhRXFIbUpZS0lGM2RQaUZmSVAxamc5ZmdzLXhMN1FPcWg1ZTRELVZ4Z0NROVZZNG5CVl9xNTJ1bFFQRzk0ZnpBYktIaUo0S3pReW53ZGpLU2dCUk9EaGItT19R?oc=5","date":"2025-09-22","type":"pipeline","source":"koreabiomed.com","summary":"GC Biopharma files Korea IND for Covid-19 mRNA shot - koreabiomed.com","headline":"GC Biopharma files Korea IND for Covid-19 mRNA shot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNVEZHSmxfVEdsblZ5NkRwdzJMcG1nNEgxNkR0ZlNYUjlNN0pFTUpxOElyU3YzSDhqLTVfazFxVGxoWDJsTWlqTmQyVlBVU0xEZWluVHBva3hYOXNPTk9zN3Blcm4yZFlnNDJQaUM2NUtsb083UHdLSmVDcjlxSERqYzZ0N25xYnBMTktVUEhoWUZVb3ZFN1c1MXhXS2l0Vlg2WW1rdV9FSFkwQ2Y3TmVRX3Q5WExZMnRSSGV3dllBaVFYQi1JMlVCUHU1WklocEQzcWFfem1tdm1tMERSTkVCSjZlZldibjNNTGtB?oc=5","date":"2025-09-08","type":"deal","source":"Business Wire","summary":"KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing - Business Wire","headline":"KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdm1tRkJyRjk5eGZDT2wzaG95SzR2NFBhbVJEcjVmQ3hvX2FuV2Q2SVBuaDdyMGFCRzR1YzZLQWZrV0t4ZnUtcGlta0tmRk9DeUN2NFZxcUdVWGZWUFFuTWxwbWRRazVodnRnMk9jVVNSOG56S2diOTQyVEVKRDBnTzN0UHNBeGRtNGlFa0FPMHpwazBuUkptZEVoVmFaNXFIbkE?oc=5","date":"2025-08-11","type":"trial","source":"BioPharma Dive","summary":"IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive","headline":"IO Biotech sees path forward for skin cancer vaccine despite study setback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNYXNWNFowRVZ0bzhPbDdDN3diallMeGQzNUxlU1NKMWNYRU1kd2JrQWgtQVJ0c1RYNUM3LXZ5eGkwbXRSdGRiVmhVVGFGcUFNY21LbUNQcF9VQUZJS2ZCdkphSENWY2VsN05Dankyd2xrOHNtVjBodGVFak9CVVlGSUF6T1d1aTJmNUQxNGExbFRIZmlCVm4tazJNOXB2ZHZ2QWJJSnZsMktpak1ScUFhSmlVcTk1QmZBN0ZYaFBDSF9WWV9sZUR3YmwwZklTd25RYmc?oc=5","date":"2025-06-18","type":"pipeline","source":"McKinsey & Company","summary":"How new approach methodologies are reshaping drug discovery - McKinsey & Company","headline":"How new approach methodologies are reshaping drug discovery - McKinsey & Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1EX2VmNEtESGljbW9pZkkzT3c5XzVZV1F6ZXlwZ0QwWjFTZ2pXRWgtUV8wZldxbXhuOHB0WmhDVm5uQ2F6aXVxWUl3Y2hMSFA2T0VsdU5QRmZWT3lmRXpPYk5vdFd6WG8tQ2FqY2VB?oc=5","date":"2025-06-10","type":"pipeline","source":"Labiotech.eu","summary":"These 18 french biotech startups could shape tomorrow’s medicine - Labiotech.eu","headline":"These 18 french biotech startups could shape tomorrow’s medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9JaENCMmhVQW1YcWNRNXQzTnpHcDkxdTNvWG5vaFI1VUpSVE1wMnIzNkJYWThCcjcwWC1PS0F5TFR0OGRQUDJPOWRLdlNfd1NlaTdoR096RnE2czBfNllUYjBTcE02MGgxSVAtX2R0RGpwQQ?oc=5","date":"2025-05-23","type":"pipeline","source":"Labiotech.eu","summary":"Finland’s biotech stars: 9 names you will want to remember - Labiotech.eu","headline":"Finland’s biotech stars: 9 names you will want to remember","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNYVZGb1d4SlV6bHhTQ0RSVURidk9lekxZR0JyZlM1OEFCcmNBcnpaNGZCZzdybERwZFNjb2VSSjJmWXJpdUMwbWMxZW93ZXY0SV8wUDRBSVRaaFRxeFpPNXFCZ3JqQUpwbEtWdFNEY2lPYURISVF2QmV4aG8zdmw0dlpxV0RFT3VnV29fRmdkdDd3WkVrM1VJaU5rb0J3aHdGbkhGeE0yRFM4clBOQWxGT0JaTFcxS3VlVHZzNHU1YjlhQlEtcG1OUjlzdEp1QjU5RlNBeXNlcHZJLVl6SVBONkdkTQ?oc=5","date":"2024-11-13","type":"pipeline","source":"PR Newswire","summary":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire","headline":"75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQcGQwVlRvTkVwUFJRSGhXV09Ib01pVS1mTm9rdUo5Y09FUC0zTjV6aHMtQ3ZKWXZxQldtRXVXUjIyVWRIZnhidDMxTkRUUGstZVdvV3FlcUx1ZnpJdXQ4LVVlc2p0WEJLM0JWQVE2anNhVmtiVXcwbmxkM19URGNvbExpQ3FLRjkzYXFqblZRZHlMT0pkYkZKREktNTU0Vi1o?oc=5","date":"2024-07-08","type":"pipeline","source":"BioSpace","summary":"Drug Developers Tap the Immune System to Supercharge ADCs - BioSpace","headline":"Drug Developers Tap the Immune System to Supercharge ADCs","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":1,"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}